Perspective Therapeutics (NYSE:CATX) Coverage Initiated at Scotiabank

Investment analysts at Scotiabank began coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report issued on Friday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $15.00 price target on the stock. Scotiabank’s target price would indicate a potential upside of 474.71% from the stock’s current price.

A number of other analysts have also commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 24th. Oppenheimer lowered their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $15.13.

Perspective Therapeutics Trading Down 3.3 %

NYSE CATX opened at $2.61 on Friday. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05. The stock has a 50 day simple moving average of $3.21 and a two-hundred day simple moving average of $7.71.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics during the 4th quarter valued at approximately $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at $34,000. National Bank of Canada FI raised its position in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Perspective Therapeutics by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics during the 4th quarter valued at about $51,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.